No J-shaped curve for efficacy in PCSK9 outcome trials

10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. Kausik Ray describes the practical implications of the PCSK9 outcome trials. In terms of efficacy, there is no J-shaped curve, meaning there is no apparent diminution of benefit to very low LDL

Video navigation menu

What did the FOURIER trial show? 00:14
Are the results what would be expected for these patients? 00:34
Effects on cognitive function: the EBBINGHAUS trial 01:06
What do we learn from the results of the SPIRE trials? 01:59
What are the take-home messages from these trials? 03:00
What are the practical implications of these trials? 03:33
Will the guidelines change? 04:15
We need better risk calculators for people with prevalent disease 05:07

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. Kausik Ray - Imperial College London, United Kingdom

Funding

Funding was provided by an unrestricted educational grant from Amgen

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.